UAE Human Insulin Market to grow at a CAGR of 2.21% to 2029
Increasing healthcare infrastructure and
a supportive regulatory environment are the major drivers for the UAE Human Insulin Market.
According to TechSci Research report, “UAE
Human Insulin Market Industry Size, Share, Trends, Competition,
Opportunity and Forecast, 2019-2029”,
UAE Human Insulin Market has valued at USD 0.20 billion in 2023 and is
anticipated to witness an impressive growth in the forecast period with a CAGR
of 2.21% through 2029. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position.
Enhanced awareness encourages
individuals to seek medical attention for symptoms associated with diabetes.
Early diagnosis allows for timely initiation of appropriate treatment, and in
many cases, insulin therapy is a vital component of diabetes management. Education
initiatives help individuals understand the role of insulin in regulating blood
glucose levels. This knowledge is essential for people with diabetes,
healthcare professionals, and the public in recognizing the significance of
insulin therapy in diabetes care.
Awareness campaigns emphasize the
importance of adherence to prescribed treatment plans. For individuals with
diabetes, this includes following medication regimens, monitoring blood glucose
levels, and incorporating insulin therapy as needed for optimal control. Education
helps dispel myths and reduce stigma associated with diabetes and insulin use.
Misconceptions and fear surrounding insulin therapy can be addressed through
accurate information, promoting greater acceptance and willingness to initiate
treatment. Increased awareness empowers individuals to actively participate in
their diabetes management. Patients who are well-informed about the benefits
and importance of insulin therapy are more likely to collaborate with
healthcare providers, leading to better treatment outcomes.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " UAE Human Insulin Market.”
In April 2022, NeoBiocon, a
collaboration between Biocon Ltd, a leading biopharmaceutical company in Asia,
and Dr. B.R. Shetty, Chairman of Neopharma in the UAE, has announced a
strategic partnership with Novartis Middle East FZE. The collaboration aims to
market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in the
United Arab Emirates (UAE). This venture is set to enhance NeoBiocon's product
portfolio in the metabolics segment, offering significant benefits to
individuals with diabetes in the UAE. Vildagliptin, an oral anti-diabetic
agent, provides consistent and robust blood sugar control for patients with
type 2 diabetes. As a class of dipeptidyl peptidase IV (DPP-IV) inhibitors, it
is known for its weight-neutral effects and a low risk of hypoglycemia.
NeoBiocon has secured approvals from the Ministry of Health-UAE for the
marketing of Jalra and Jalra-M in the country, with the launch scheduled for
January 2016.
Many
pharmaceutical companies source raw materials or components globally.
Disruptions in the supply chain, such as transportation issues, customs delays,
or manufacturing challenges in other countries, can impact the availability of
insulin products in the UAE. Transportation and logistics are critical
components of the pharmaceutical supply chain. Delays in shipping, customs
clearance, or transportation issues can affect the timely delivery of insulin
products to distributors and pharmacies in the UAE. Insulin products have
specific storage and handling requirements to maintain their efficacy.
Disruptions in temperature-controlled storage facilities or issues with
adherence to proper handling practices can compromise the quality of insulin
products. Events such as pandemics, natural disasters, or other global health
emergencies can disrupt supply chains and impact the production, distribution,
and transportation of pharmaceutical products, including insulin. Changes
in trade regulations, tariffs, or other geopolitical factors can affect the
flow of goods across borders. This can impact the importation of insulin
products into the UAE and contribute to supply chain disruptions.
UAE Human Insulin Market is
segmented based on Indication, Route of Administration, Type, Onset Time, Products,
and by region.
Based on the Type, UAE
Human Insulin Market is
segmented into Basal, Bolus, Pre-mixed, Biosimilar, Traditional. A biosimilar
type of human insulin refers to a biological product that is highly like an
already-approved reference or originator insulin. Biosimilars are not identical
copies of the reference product but demonstrate similarity in terms of quality,
safety, and efficacy. They are developed to be comparable alternatives to
existing biologic drugs, offering a more cost-effective option while
maintaining therapeutic effectiveness. Unlike traditional chemical drugs, which are
typically synthesized through chemical processes, biological products,
including insulin, are complex molecules produced in living cells using
biotechnological methods. Biosimilar insulins are designed to have a highly
similar structure to reference insulin. This similarity is established through
rigorous analytical and functional comparisons, demonstrating that the
biosimilar is comparable to the reference product in terms of safety and
efficacy.
Based on Region, Abu Dhabi region held the largest share
in the UAE Human
Insulin Market. The presence of research and development
centers focused on diabetes and related healthcare in Abu Dhabi might attract
pharmaceutical companies and contribute to advancements in insulin products,
giving the region a competitive edge. Well-established distribution networks
and logistical advantages in Abu Dhabi can facilitate the efficient supply and
distribution of insulin products, making it a preferred location for market
dominance. Abu Dhabi has specific healthcare policies or regulations that
create a conducive environment for pharmaceutical companies, it could lead to
the concentration of market activities in the region.
Some of the major companies operating in
the UAE Human
Insulin Market include:
- Novo
Nordisk Pharma Gulf FZ-LLC
- Sanofi UAE
- Baxter
International UAE
- B. Braun
Medical Gulf FZ – LLC
- Eli Lilly
and Company UAE
- Becton
Dickinson And Company UAE
- Gulf
Pharmaceutical Industries P.S.C. (Julphar)
Download free Sample Report
Customers
can also request 10% free customization on this report.
“Certain areas,
particularly in Dubai, are projected to exert significant demand for Human
Insulin. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the UAE Human Insulin Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
UAE Human Insulin Market by Indication
(Type I Diabetes, Type Il Diabetes), By Route of Administration (Subcutaneous,
Nasal, Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus,
Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting,
Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By
Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region, By Competition Forecast & Opportunities, 2019-2029F has evaluated the future growth potential of UAE
Human Insulin Market and provides statistics & information on market size, structure,
and future market growth. The report intends to provide innovative market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in UAE Human Insulin Market.
Contact
Mr. Ken Mathews
Techsci Research
LLC
420 Lexington
Avenue, Suite 300, New York, United States- 10170
M: +13322586602
Email: [email protected]
Website: https://www.techsciresearch.com